Prusogliptin vs Saxagliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Prusogliptin · Shanzeping

Marketed by CSPC Pharmaceutical Group and partners

Phase 3 in Type 2 Diabetessmall molecule
Reliable signal

NCT04161430 · Phase 3 · completed

In this randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial, 766 patients with type 2 diabetes were randomized to DBPR108, sitagliptin, or placebo. DBPR108 reduced HbA1c significantly more than placebo at 24 weeks, with a treatment difference whose confidence interval excluded no effect.

Reported efficacy

Change from baseline in HbA1c (%) compared to placebo comparator at week 24 (Baseline, week 24): HbA1c change from baseline at week 24: -0.63% (DBPR108) vs -0.02% (placebo); treatment difference -0.61 percentage points (95% CI -0.77% to -0.44%). DBPR108 was superior to placebo. (met)

Result source: NCT04161430

Saxagliptin · Onglyza

Rights held by AstraZeneca and partners; US product discontinued

Approved in Type 2 Diabetessmall molecule
Reliable signal

NCT00121667 · Phase 3 · completed

Large randomized, double-blind, placebo-controlled phase 3 trial (743 treated participants across three saxagliptin doses and one placebo arm, all on background metformin). The primary endpoint was change from baseline in hemoglobin A1c at Week 24, an accepted hard glycemic measure for type 2 diabetes, and every saxagliptin dose showed a statistically significant improvement versus placebo (adjusted differences of -0.73, -0.83, and -0.72 percentage points, each p<0.0001). Because the trial was adequately powered, double-blind, and placebo-controlled, and the primary comparison was met, this is strong evidence for saxagliptin's efficacy.

Next expected readout: February 2027 · NCT02969798 (registry estimate)

Reported efficacy

Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07) (met)

Result source: NCT00121667

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPrusogliptinSaxagliptin
HbA1c, change-0.6% vs -0.0%a−0.6 vs placebowk 24NCT04161430
1 other result
-0.7% vs -0.3%−0.4 vs placebo5 mg · wk 24 · n 300NCT00757588
19 other results
  • 7.1% vs 7.5% 5 mg · wk 24 · n 275 · Phase 3 · primary NCT00661362
  • -0.5% vs -0.2% 5 mg · wk 24 · n 139 · Phase 3 · primary NCT01619059
  • -0.8% vs -0.1% wk 24 · n 158 · Phase 3 · primary NCT01646320
  • -0.7% vs -0.1% wk 24 · n 127 · Phase 3 · primary NCT01128153
  • 0.1% vs 0.5% wk 26 · n 82 · Phase 3 · primary NCT03199053
  • -0.7% vs 0.6% wk 16 · n 4 · Phase 3 · primary NCT01204775
  • -1% vs 0.9% wk 16 · n 4 · Phase 3 · primary NCT01434186
  • -1.4% vs -1.0% dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 218 · Phase 3 · primary NCT02419612
  • -1.7% vs -1.5% wk 24 · n 319 · Phase 3 · primary NCT02551874
  • -1.0% vs -0.7% wk 24 · n 290 · Phase 3 · primary NCT02681094
  • -1.4% vs -1.1% wk 26 · n 224 · Phase 3 · primary NCT02284893
  • -0.2% vs -0.7% 5 mg · wk 26 · n 25 · Phase 3 · secondary NCT03199053
  • 0.1% vs -0.7% 2.5 mg · wk 26 · n 24 · Phase 3 · secondary NCT03199053
  • -0.8% vs -1.0% 10mg · wk 52 · n 311 · Phase 4 · primary NCT02471404
  • -1.2% vs -1.0% 5mg and 10mg · wk 52 · n 312 · Phase 4 · primary NCT02471404
  • -0.8% vs -0.8% wk 24 · n 238 · Phase 4 · primary NCT02243176
  • -0.8% vs -0.8% wk 24 · n 219 · Phase 4 · primary NCT02243176
  • -0.5% vs -0.4% wk 24 · n 146 · Phase 4 · primary NCT01006590
  • -0.4% vs -0.6% 5 mg · wk 52 · n 353 · Phase 4 · secondary NCT01006603
Body weight, change (kg)—Not posted · NCT04218734-1.9 vs -0.4−1.5 vs placebowk 24 · n 158NCT01646320
7 other results
  • -3.1 vs 0.9 dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 224 · Phase 3 · secondary NCT02419612
  • -1.9 vs -0.5 wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • -1.5 vs 2.1 wk 24 · n 319 · Phase 3 · secondary NCT02551874
  • -2.0 vs -0.4 wk 24 · n 290 · Phase 3 · secondary NCT02681094
  • -3.5 vs 1.8 10mg · wk 52 · n 311 · Phase 4 · secondary NCT02471404
  • -3.1 vs 1.8 5mg and 10mg · wk 52 · n 312 · Phase 4 · secondary NCT02471404
  • -1.4 vs -2.0 wk 24 · n 238 · Phase 4 · secondary NCT02243176
HbA1c below 7%—Not posted · NCT0421873444.4% vs 16.6%+27.8 vs placebo10 mg · wk 24 · n 180NCT00121667
15 other results
  • 41.1% vs 23.9% 10 mg · wk 24 · n 95 · Phase 3 · secondary NCT00121641
  • 43.5% vs 16.6% 5 mg · wk 24 · n 186 · Phase 3 · secondary NCT00121667
  • 37.9% vs 23.9% 5 mg · wk 24 · n 103 · Phase 3 · secondary NCT00121641
  • 22.1% vs 13.3% 5 mg · wk 24 · n 104 · Phase 3 · secondary NCT00918879
  • 45.8% vs 28.8% 5 mg · wk 24 · n 277 · Phase 3 · secondary NCT00698932
  • 37.1% vs 16.6% 2.5 mg · wk 24 · n 186 · Phase 3 · secondary NCT00121667
  • 35% vs 23.9% 2.5 mg · wk 24 · n 100 · Phase 3 · secondary NCT00121641
  • 37.5% vs 24.2% 2.5 mg · wk 12 · n 73 · Phase 3 · secondary NCT00885378
  • 21.3% vs 10% wk 26 · n 61 · Phase 3 · secondary NCT03199053
  • 36.7% vs 13.3% wk 24 · n 158 · Phase 3 · secondary NCT01646320
  • 21.4% vs 11.7% dapagliflozin 10 mg, saxagliptin 5 mg · wk 156 · n 227 · Phase 3 · secondary NCT02419612
  • 44.3% vs 34.3% dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 227 · Phase 3 · secondary NCT02419612
  • 37.3% vs 25.1% wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • 37.2% vs 26.1% wk 18 · n 137 · Phase 3 · secondary NCT00960076
  • 38.3% vs 41.5% wk 24 · n 230 · Phase 4 · secondary NCT02243176
Fasting plasma glucose, change—Not posted · NCT04218734-0.6 vs -0.3−0.2 vs placebo5 mg · wk 24 · n 300NCT00757588
11 other results
  • -0.5 vs -0.3 5 mg · wk 24 · n 139 · Phase 3 · secondary NCT01619059
  • 0.1 vs 0.2 wk 26 · n 80 · Phase 3 · secondary NCT03199053
  • -1.8 vs -0.3 wk 24 · n 158 · Phase 3 · secondary NCT01646320
  • -0.3 vs 0.1 wk 24 · n 121 · Phase 3 · secondary NCT01128153
  • -1.8 vs -0.6 wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • -2.4 vs -1.0 5 mg · wk 26 · n 25 · Phase 3 · secondary NCT03199053
  • -0.6 vs -1.0 2.5 mg · wk 26 · n 23 · Phase 3 · secondary NCT03199053
  • -1.6 vs -1.5 10mg · wk 52 · n 311 · Phase 4 · secondary NCT02471404
  • -0.7 vs -1.3 5 mg · wk 52 · n 344 · Phase 4 · secondary NCT01006603
  • -2.1 vs -1.5 5mg and 10mg · wk 52 · n 312 · Phase 4 · secondary NCT02471404
  • -1.0 vs -1.0 wk 24 · n 238 · Phase 4 · secondary NCT02243176
3-point MACE (% with event)—Not posted · NCT042187347.4% vs 7.4%±0 vs placebon 8280NCT01107886

HbA1c, change

Prusogliptin
-0.6% vs -0.0%a−0.6 vs placebowk 24NCT04161430
1 other result
Saxagliptin
-0.7% vs -0.3%−0.4 vs placebo5 mg · wk 24 · n 300NCT00757588
19 other results
  • 7.1% vs 7.5% 5 mg · wk 24 · n 275 · Phase 3 · primary NCT00661362
  • -0.5% vs -0.2% 5 mg · wk 24 · n 139 · Phase 3 · primary NCT01619059
  • -0.8% vs -0.1% wk 24 · n 158 · Phase 3 · primary NCT01646320
  • -0.7% vs -0.1% wk 24 · n 127 · Phase 3 · primary NCT01128153
  • 0.1% vs 0.5% wk 26 · n 82 · Phase 3 · primary NCT03199053
  • -0.7% vs 0.6% wk 16 · n 4 · Phase 3 · primary NCT01204775
  • -1% vs 0.9% wk 16 · n 4 · Phase 3 · primary NCT01434186
  • -1.4% vs -1.0% dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 218 · Phase 3 · primary NCT02419612
  • -1.7% vs -1.5% wk 24 · n 319 · Phase 3 · primary NCT02551874
  • -1.0% vs -0.7% wk 24 · n 290 · Phase 3 · primary NCT02681094
  • -1.4% vs -1.1% wk 26 · n 224 · Phase 3 · primary NCT02284893
  • -0.2% vs -0.7% 5 mg · wk 26 · n 25 · Phase 3 · secondary NCT03199053
  • 0.1% vs -0.7% 2.5 mg · wk 26 · n 24 · Phase 3 · secondary NCT03199053
  • -0.8% vs -1.0% 10mg · wk 52 · n 311 · Phase 4 · primary NCT02471404
  • -1.2% vs -1.0% 5mg and 10mg · wk 52 · n 312 · Phase 4 · primary NCT02471404
  • -0.8% vs -0.8% wk 24 · n 238 · Phase 4 · primary NCT02243176
  • -0.8% vs -0.8% wk 24 · n 219 · Phase 4 · primary NCT02243176
  • -0.5% vs -0.4% wk 24 · n 146 · Phase 4 · primary NCT01006590
  • -0.4% vs -0.6% 5 mg · wk 52 · n 353 · Phase 4 · secondary NCT01006603

Body weight, change (kg)

Prusogliptin
—Not posted · NCT04218734
Saxagliptin
-1.9 vs -0.4−1.5 vs placebowk 24 · n 158NCT01646320
7 other results
  • -3.1 vs 0.9 dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 224 · Phase 3 · secondary NCT02419612
  • -1.9 vs -0.5 wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • -1.5 vs 2.1 wk 24 · n 319 · Phase 3 · secondary NCT02551874
  • -2.0 vs -0.4 wk 24 · n 290 · Phase 3 · secondary NCT02681094
  • -3.5 vs 1.8 10mg · wk 52 · n 311 · Phase 4 · secondary NCT02471404
  • -3.1 vs 1.8 5mg and 10mg · wk 52 · n 312 · Phase 4 · secondary NCT02471404
  • -1.4 vs -2.0 wk 24 · n 238 · Phase 4 · secondary NCT02243176

HbA1c below 7%

Prusogliptin
—Not posted · NCT04218734
Saxagliptin
44.4% vs 16.6%+27.8 vs placebo10 mg · wk 24 · n 180NCT00121667
15 other results
  • 41.1% vs 23.9% 10 mg · wk 24 · n 95 · Phase 3 · secondary NCT00121641
  • 43.5% vs 16.6% 5 mg · wk 24 · n 186 · Phase 3 · secondary NCT00121667
  • 37.9% vs 23.9% 5 mg · wk 24 · n 103 · Phase 3 · secondary NCT00121641
  • 22.1% vs 13.3% 5 mg · wk 24 · n 104 · Phase 3 · secondary NCT00918879
  • 45.8% vs 28.8% 5 mg · wk 24 · n 277 · Phase 3 · secondary NCT00698932
  • 37.1% vs 16.6% 2.5 mg · wk 24 · n 186 · Phase 3 · secondary NCT00121667
  • 35% vs 23.9% 2.5 mg · wk 24 · n 100 · Phase 3 · secondary NCT00121641
  • 37.5% vs 24.2% 2.5 mg · wk 12 · n 73 · Phase 3 · secondary NCT00885378
  • 21.3% vs 10% wk 26 · n 61 · Phase 3 · secondary NCT03199053
  • 36.7% vs 13.3% wk 24 · n 158 · Phase 3 · secondary NCT01646320
  • 21.4% vs 11.7% dapagliflozin 10 mg, saxagliptin 5 mg · wk 156 · n 227 · Phase 3 · secondary NCT02419612
  • 44.3% vs 34.3% dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 227 · Phase 3 · secondary NCT02419612
  • 37.3% vs 25.1% wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • 37.2% vs 26.1% wk 18 · n 137 · Phase 3 · secondary NCT00960076
  • 38.3% vs 41.5% wk 24 · n 230 · Phase 4 · secondary NCT02243176

Fasting plasma glucose, change

Prusogliptin
—Not posted · NCT04218734
Saxagliptin
-0.6 vs -0.3−0.2 vs placebo5 mg · wk 24 · n 300NCT00757588
11 other results
  • -0.5 vs -0.3 5 mg · wk 24 · n 139 · Phase 3 · secondary NCT01619059
  • 0.1 vs 0.2 wk 26 · n 80 · Phase 3 · secondary NCT03199053
  • -1.8 vs -0.3 wk 24 · n 158 · Phase 3 · secondary NCT01646320
  • -0.3 vs 0.1 wk 24 · n 121 · Phase 3 · secondary NCT01128153
  • -1.8 vs -0.6 wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • -2.4 vs -1.0 5 mg · wk 26 · n 25 · Phase 3 · secondary NCT03199053
  • -0.6 vs -1.0 2.5 mg · wk 26 · n 23 · Phase 3 · secondary NCT03199053
  • -1.6 vs -1.5 10mg · wk 52 · n 311 · Phase 4 · secondary NCT02471404
  • -0.7 vs -1.3 5 mg · wk 52 · n 344 · Phase 4 · secondary NCT01006603
  • -2.1 vs -1.5 5mg and 10mg · wk 52 · n 312 · Phase 4 · secondary NCT02471404
  • -1.0 vs -1.0 wk 24 · n 238 · Phase 4 · secondary NCT02243176

3-point MACE (% with event)

Prusogliptin
—Not posted · NCT04218734
Saxagliptin
7.4% vs 7.4%±0 vs placebon 8280NCT01107886
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Prusogliptin: 3 of 4 rows · Saxagliptin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPrusogliptinSaxagliptin
Dropout rate
0%600 mga
NCT01650324 · Phase 1 · registry result, not featured evidence
show 3 more results
0%300 mg
NCT01650324 · Phase 1 · registry result, not featured evidence
0%100 mg
NCT01650324 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01650324 · Phase 1 · registry result, not featured evidence
22.7%10 mgb
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 43 more results
25.1%5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
22.9%2.5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
29.6%10 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
35.8%5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
28.4%2.5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%
NCT02024477 · Phase 4 · registry result, not featured evidence
10.5%10mg
NCT02471404 · Phase 4 · registry result, not featured evidence
4.5%5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
5.7%
NCT02243176 · Phase 4 · registry result, not featured evidence
17.1%
NCT01608724 · Phase 4 · registry result, not featured evidence
2.4%
NCT01107886 · Phase 4 · registry result, not featured evidence
19.7%5 mg
NCT01006603 · Phase 4 · registry result, not featured evidence
19%
NCT01006590 · Phase 4 · registry result, not featured evidence · add on
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
5.7%Saxagliptin
NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy
7.5%dapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
8.6%
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
12.6%
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
8.2%
NCT02284893 · Phase 3 · registry result, not featured evidence · combination
25%
NCT01204775 · Phase 3 · registry result, not featured evidence
0%
NCT01434186 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
6.8%Saxagliptin Plus Insulin
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
—DAPA + SAXA + MET
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
7.5%Dapa+Saxa+Met
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
7.2%5 mg
NCT01619059 · Phase 3 · registry result, not featured evidence · combination
—
NCT01606007 · Phase 3 · registry result, not featured evidence · combination
12.4%
NCT01128153 · Phase 3 · registry result, not featured evidence
5.8%
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
61.4%
NCT00575588 · Phase 3 · registry result, not featured evidence · combination
5.6%5 mg
NCT00918879 · Phase 3 · registry result, not featured evidence
4.3%5 mg + Metformin XR 1500 mg
NCT00918138 · Phase 3 · registry result, not featured evidence · combination
11.8%5 mg
NCT00757588 · Phase 3 · registry result, not featured evidence · combination
50.6%
NCT00614939 · Phase 3 · registry result, not featured evidence
10.8%2.5 mg
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
15%5 mg
NCT00374907 · Phase 3 · registry result, not featured evidence
7.7%5 mg
NCT00698932 · Phase 3 · registry result, not featured evidence
10.2%5 mg
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
Discontinued due to AEs
—600 mga
NCT01650324 · Phase 1 · registry result, not featured evidence
show 3 more results
—300 mg
NCT01650324 · Phase 1 · registry result, not featured evidence
—100 mg
NCT01650324 · Phase 1 · registry result, not featured evidence
—25 mg
NCT01650324 · Phase 1 · registry result, not featured evidence
2.8%10 mgb
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 43 more results
3.1%5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.6%2.5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.1%10 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.8%5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.9%2.5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
—
NCT02024477 · Phase 4 · registry result, not featured evidence
2.2%10mg
NCT02471404 · Phase 4 · registry result, not featured evidence
0.3%5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
0.8%
NCT02243176 · Phase 4 · registry result, not featured evidence
2%
NCT01608724 · Phase 4 · registry result, not featured evidence
—
NCT01107886 · Phase 4 · registry result, not featured evidence
4.2%5 mg
NCT01006603 · Phase 4 · registry result, not featured evidence
1.4%
NCT01006590 · Phase 4 · registry result, not featured evidence · add on
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—Saxagliptin
NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy
0.4%dapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
—
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
3.4%
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
0.4%
NCT02284893 · Phase 3 · registry result, not featured evidence · combination
—
NCT01204775 · Phase 3 · registry result, not featured evidence
—
NCT01434186 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
1.7%Saxagliptin Plus Insulin
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
—DAPA + SAXA + MET
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
1.9%Dapa+Saxa+Met
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
0%5 mg
NCT01619059 · Phase 3 · registry result, not featured evidence · combination
—
NCT01606007 · Phase 3 · registry result, not featured evidence · combination
0.8%
NCT01128153 · Phase 3 · registry result, not featured evidence
0.7%
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
2.6%
NCT00575588 · Phase 3 · registry result, not featured evidence · combination
—5 mg
NCT00918879 · Phase 3 · registry result, not featured evidence
—5 mg + Metformin XR 1500 mg
NCT00918138 · Phase 3 · registry result, not featured evidence · combination
2%5 mg
NCT00757588 · Phase 3 · registry result, not featured evidence · combination
5.9%
NCT00614939 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
—5 mg
NCT00374907 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT00698932 · Phase 3 · registry result, not featured evidence
1.8%5 mg
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
Serious AEs
0%600 mga
NCT01650324 · Phase 1 · registry result, not featured evidence
show 3 more results
0%300 mg
NCT01650324 · Phase 1 · registry result, not featured evidence
0%100 mg
NCT01650324 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01650324 · Phase 1 · registry result, not featured evidence
12.2%10 mgb
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 43 more results
14.1%5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
12%2.5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.2%10 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
17%5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
10.8%2.5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.8%
NCT02024477 · Phase 4 · registry result, not featured evidence
12.5%10mg
NCT02471404 · Phase 4 · registry result, not featured evidence
7.1%5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
2.1%
NCT02243176 · Phase 4 · registry result, not featured evidence
1.8%
NCT01608724 · Phase 4 · registry result, not featured evidence
25.5%
NCT01107886 · Phase 4 · registry result, not featured evidence
11.4%5 mg
NCT01006603 · Phase 4 · registry result, not featured evidence
4.1%
NCT01006590 · Phase 4 · registry result, not featured evidence · add on
0%5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
3.8%5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence · combination
2.3%2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
1.6%2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
4.9%2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—Saxagliptin
NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy
12.8%dapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
6.2%
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
2.4%
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
3.9%
NCT02284893 · Phase 3 · registry result, not featured evidence · combination
0%
NCT01204775 · Phase 3 · registry result, not featured evidence
0%
NCT01434186 · Phase 3 · registry result, not featured evidence
5.1%5 mg QD
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
—Saxagliptin Plus Insulin
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
4.4%DAPA + SAXA + MET
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
—Dapa+Saxa+Met
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
4.6%5 mg
NCT01619059 · Phase 3 · registry result, not featured evidence · combination
1.1%
NCT01606007 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT01128153 · Phase 3 · registry result, not featured evidence
0%
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
12.6%
NCT00575588 · Phase 3 · registry result, not featured evidence · combination
0%5 mg
NCT00918879 · Phase 3 · registry result, not featured evidence
2.2%5 mg + Metformin XR 1500 mg
NCT00918138 · Phase 3 · registry result, not featured evidence · combination
8.2%5 mg
NCT00757588 · Phase 3 · registry result, not featured evidence · combination
27.1%
NCT00614939 · Phase 3 · registry result, not featured evidence
1.4%2.5 mg
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
5%5 mg
NCT00374907 · Phase 3 · registry result, not featured evidence
2.8%5 mg
NCT00698932 · Phase 3 · registry result, not featured evidence
2.8%5 mg
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
Most frequent reported AEs
600 mga
haematuria 16.7% (placebo 0%)
infection 16.7% (placebo 0%)
ligament sprain 16.7% (placebo 0%)
NCT01650324 · Phase 1 · registry result, not featured evidence
show 3 more results
300 mg
platelet count decreased 16.7% (placebo 0%)
haematuria 0% (placebo 0%)
infection 0% (placebo 0%)
NCT01650324 · Phase 1 · registry result, not featured evidence
100 mg
haematuria 0% (placebo 0%)
infection 0% (placebo 0%)
ligament sprain 0% (placebo 0%)
NCT01650324 · Phase 1 · registry result, not featured evidence
25 mg
haematuria 0% (placebo 0%)
infection 0% (placebo 0%)
ligament sprain 0% (placebo 0%)
NCT01650324 · Phase 1 · registry result, not featured evidence
10 mgb
influenza 15.5% (placebo 15.1%)
nasopharyngitis 15.5% (placebo 14%)
headache 13.3% (placebo 12.3%)
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 37 more results
5 mg
influenza 16.2% (placebo 15.1%)
nasopharyngitis 14.7% (placebo 14%)
arthralgia 10.5% (placebo 6.7%)
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.5 mg
diarrhoea 15.1% (placebo 12.8%)
nasopharyngitis 14.6% (placebo 14%)
headache 14.1% (placebo 12.3%)
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
10 mg
arthralgia 16.3% (placebo 7.4%)
headache 16.3% (placebo 16.8%)
influenza 15.3% (placebo 6.3%)
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
upper respiratory tract infection 15.1% (placebo 15.8%)
urinary tract infection 13.2% (placebo 8.4%)
headache 12.3% (placebo 16.8%)
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.5 mg
diarrhoea 13.7% (placebo 8.4%)
upper respiratory tract infection 11.8% (placebo 15.8%)
influenza 10.8% (placebo 6.3%)
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
10mg
nasopharyngitis 9.3%
NCT02471404 · Phase 4 · registry result, not featured evidence
5mg and 10mg
nasopharyngitis 9.9%
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
hyperlipidaemia 6.2%
hyperlipidaemia 3.7%
abdominal distension 1.2%
NCT02243176 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 2.7%
dizziness 2.6%
NCT01608724 · Phase 4 · registry result, not featured evidence
diabetes mellitus 6.5% (placebo 8.1%)
dizziness 4.5% (placebo 4.2%)
hypertension 4.2% (placebo 3.9%)
NCT01107886 · Phase 4 · registry result, not featured evidence
5 mg
nasopharyngitis 6.4%
arthralgia 4.7%
diarrhoea 4.2%
NCT01006603 · Phase 4 · registry result, not featured evidence
hypoglycaemia 6.8%
diarrhoea 6.1%
nasopharyngitis 5.4%
NCT01006590 · Phase 4 · registry result, not featured evidence · add on
5 mg
toothache 7.7% (placebo 0%)
acne 3.8% (placebo 0%)
animal bite 3.8% (placebo 0%)
NCT03199053 · Phase 3 · registry result, not featured evidence
5 mg
aphthous ulcer 3.8% (placebo 0%)
back pain 3.8% (placebo 2.6%)
colitis 3.8% (placebo 0%)
NCT03199053 · Phase 3 · registry result, not featured evidence
5 mg
nasopharyngitis 15.4% (placebo 2.6%)
asthma 7.7% (placebo 0%)
covid-19 7.7% (placebo 2.6%)
NCT03199053 · Phase 3 · registry result, not featured evidence · combination
2.5 mg
vitamin d deficiency 4.5% (placebo 6.6%)
nausea 3.4% (placebo 0%)
urinary tract infection 3.4% (placebo 5.3%)
NCT03199053 · Phase 3 · registry result, not featured evidence
2.5 mg
influenza 4.9% (placebo 2.6%)
bronchitis 1.6% (placebo 0%)
chronic sinusitis 1.6% (placebo 0%)
NCT03199053 · Phase 3 · registry result, not featured evidence
2.5 mg
covid-19 6.6% (placebo 2.6%)
upper respiratory tract infection 6.6% (placebo 2.6%)
urinary tract infection 4.9% (placebo 5.3%)
NCT03199053 · Phase 3 · registry result, not featured evidence
dapagliflozin 10 mg, saxagliptin 5 mg
urinary tract infection 13.7%
upper respiratory tract infection 10.1%
headache 7.9%
NCT02419612 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 7.7%
upper respiratory tract infection 5.2%
headache 3.7%
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
glomerular filtration rate decreased 4.1%
pollakiuria 2.4%
urinary tract infection 2.4%
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
nasopharyngitis 7.8%
headache 5.6%
urinary tract infection 4.3%
NCT02284893 · Phase 3 · registry result, not featured evidence · combination
oropharyngeal pain 50% (placebo 25%)
acne 25% (placebo 0%)
cough 25% (placebo 25%)
NCT01204775 · Phase 3 · registry result, not featured evidence
headache 50% (placebo 0%)
abdominal pain upper 25% (placebo 0%)
back pain 25% (placebo 0%)
NCT01434186 · Phase 3 · registry result, not featured evidence
5 mg QD
hypoglycaemia 21.8% (placebo 23.8%)
upper respiratory tract infection 2.6% (placebo 4.3%)
urinary tract infection 2.6% (placebo 0.9%)
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
urinary tract infection 9.4% (placebo 10%)
influenza 7.5% (placebo 7.5%)
headache 6.9% (placebo 8.1%)
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
5 mg
urinary tract infection 7.2% (placebo 6.8%)
headache 5.9% (placebo 7.4%)
nasopharyngitis 5.9% (placebo 4.9%)
NCT01619059 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 6.2% (placebo 9.4%)
diarrhoea 5.4% (placebo 3.9%)
hypertension 5.4% (placebo 1.6%)
NCT01128153 · Phase 3 · registry result, not featured evidence
diarrhoea 5.8%
urinary tract infection 5.1%
nasopharyngitis 4.3%
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 10.7%
diarrhoea 5.8%
upper respiratory tract infection 5.8%
NCT00575588 · Phase 3 · registry result, not featured evidence · combination
5 mg
urinary tract infection 8.4% (placebo 9.4%)
NCT00918879 · Phase 3 · registry result, not featured evidence
5 mg + Metformin XR 1500 mg
cough 6.5%
NCT00918138 · Phase 3 · registry result, not featured evidence · combination
5 mg
urinary tract infection 7.6% (placebo 7.9%)
nasopharyngitis 6.3% (placebo 6.6%)
upper respiratory tract infection 6.3% (placebo 7.3%)
NCT00757588 · Phase 3 · registry result, not featured evidence · combination
hypoglycaemia 28.2% (placebo 29.4%)
anaemia 5.9% (placebo 8.2%)
hypertension 5.9% (placebo 5.9%)
NCT00614939 · Phase 3 · registry result, not featured evidence
5 mg
headache 25% (placebo 18.8%)
muscle spasms 25% (placebo 0%)
infusion site pain 20% (placebo 12.5%)
NCT00374907 · Phase 3 · registry result, not featured evidence
5 mg
upper respiratory tract infection 6.3% (placebo 7.7%)
NCT00698932 · Phase 3 · registry result, not featured evidence
5 mg
upper respiratory tract infection 6.7% (placebo 4.5%)
NCT00661362 · Phase 3 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 38 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Saxagliptin

HbA1c -0.58% (n=180) vs 0.13% (n=175) placebo @ 24wk10 mg
absolute change · percentage points
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 8 more results
-0.54% (n=98) vs 0.19% (n=95) placebo @ 24wk10 mg
Adjusted Mean Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.69% (n=186) vs 0.13% (n=175) placebo @ 24wk5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.46% (n=106) vs 0.19% (n=95) placebo @ 24wk5 mg
Adjusted Mean Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.84% (n=277) vs -0.34% (n=274) placebo @ 24wk5 mg
Adjusted Mean Change from Baseline
NCT00698932 · Phase 3 · registry result, not featured evidence
-0.59% (n=186) vs 0.13% (n=175) placebo @ 24wk2.5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.43% (n=102) vs 0.19% (n=95) placebo @ 24wk2.5 mg
Adjusted Mean Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.56% (n=74) vs -0.22% (n=84) placebo @ 12wk2.5 mg
Adjusted Mean Change From Baseline
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
-0.86% (n=81) vs -0.44% (n=83) placebo @ 12wk
Adjusted Mean Change from Baseline
NCT00614939 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose -1.14 vs 0.07 placebo mmol/L @ 24wk10 mg
absolute change · mmol/L
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -20.5 mg/dL as posted
show 6 more results
-1.22 vs 0.07 placebo mmol/L @ 24wk*5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -22.03 mg/dL as posted
-0.9 vs -0.17 placebo mmol/L @ 24wk5 mg
Adjusted mean change from Baseline
NCT00698932 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.17 placebo mmol/L @ 24wk*5 mg
Adjusted mean change from Baseline
NCT00698932 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -16.13 mg/dL as posted
-0.79 vs 0.07 placebo mmol/L @ 24wk*2.5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -14.31 mg/dL as posted
-0.52 vs -0.2 Metformin mmol/L @ 4wk*5 mg + Metformin XR 1500 mg
Adjusted mean change from baseline
NCT00918138 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -9.3 mg/dL as posted
-0.76 vs -0.23 placebo mmol/L @ 12wk*2.5 mg
Adjusted Mean Change from Baseline
NCT00885378 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -13.73 mg/dL as posted
HbA1c Less Than 7% 44.4% (n=180) vs 16.6% (n=175) placebo @ 24wk10 mg
responder rate · % of participants
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 15 more results
41.1% (n=95) vs 23.9% (n=92) placebo @ 24wk10 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
44.3% (n=227) vs 34.3% (n=216) Glimepiride @ 52wkdapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
21.4% (n=227) vs 11.7% (n=216) Glimepiride @ 156wkdapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
43.5% (n=186) vs 16.6% (n=175) placebo @ 24wk5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
37.9% (n=103) vs 23.9% (n=92) placebo @ 24wk5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
22.1% (n=104) vs 13.3% (n=105) placebo @ 24wk5 mg
NCT00918879 · Phase 3 · registry result, not featured evidence
45.8% (n=277) vs 28.8% (n=274) placebo @ 24wk5 mg
NCT00698932 · Phase 3 · registry result, not featured evidence
37.1% (n=186) vs 16.6% (n=175) placebo @ 24wk2.5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
35% (n=100) vs 23.9% (n=92) placebo @ 24wk2.5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
37.5% (n=73) vs 24.2% (n=84) placebo @ 12wk2.5 mg
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
38.3% (n=230) vs 41.5% (n=229) Acarbose @ 24wk
NCT02243176 · Phase 4 · registry result, not featured evidence
21.3% (n=61) vs 10% (n=50) placebo @ 26wk
NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy
37.3% (n=224) vs 25.1% (n=219) Sita + Met @ 26wk
NCT02284893 · Phase 3 · registry result, not featured evidence · background therapy
36.7% (n=158) vs 13.3% (n=158) placebo @ 24wk
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
37.2% (n=137) vs 26.1% (n=142) Metformin (DB) + Metformin (OL) @ 18wk
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
Postprandial Glucose AUC -8137 vs -3291 placebo mg @ 24wk10 mg
absolute change · mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-9586 vs -3291 placebo mg @ 24wk5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
-7534 vs -4255 placebo mg @ 24wk5 mg
Adjusted mean change from Baseline
NCT00698932 · Phase 3 · registry result, not featured evidence
-8891 vs -3291 placebo mg @ 24wk2.5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
Fasting Plasma Glucose -0.93 vs 0.34 placebo mmol/L @ 24wk10 mg
absolute change · mmol/L
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -16.75 mg/dL as posted
show 4 more results
-0.48 vs 0.34 placebo mmol/L @ 24wk*5 mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -8.67 mg/dL as posted
-1.14 vs -0.58 placebo mmol/L @ 24wk5 mg
Adjusted Change from Baseline
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
-1.14 vs -0.58 placebo mmol/L @ 24wk*5 mg
Adjusted Change from Baseline
NCT00661362 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -20.52 mg/dL as posted
-0.81 vs 0.34 placebo mmol/L @ 24wk*2.5 mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -14.53 mg/dL as posted
Postprandial Glucose AUC -8084 vs -646.6 placebo mg @ 24wk10 mg
absolute change · mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 2 more results
-6896 vs -646.6 placebo mg @ 24wk5 mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
-6868 vs -646.6 placebo mg @ 24wk2.5 mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c 6.8% (n=21) vs 6.6% (n=21) placebo @ 6wk
absolute value · percentage points
Visit 2 - Week 6
NCT02024477 · Phase 4 · registry result, not featured evidence
HbA1c 6.7% (n=21) vs 6.5% (n=21) placebo @ 12wk
absolute value · percentage points
Visit 3 - Week 12
NCT02024477 · Phase 4 · registry result, not featured evidence
Weight -3.54 vs 1.76 Glimepiride kg @ 52wk10mg
absolute change · kg
NCT02471404 · Phase 4 · registry result, not featured evidence
show 7 more results
-3.11 vs 0.95 Glimepiride kg @ 52wkdapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
-3.15 vs 1.76 Glimepiride kg @ 52wk5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
-1.36 vs -2.05 Acarbose kg @ 24wk
NCT02243176 · Phase 4 · registry result, not featured evidence
-1.5 vs 2.14 Titrated Insulin kg @ 24wk
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
-2.01 vs -0.41 Saxagliptin + Metformin kg @ 24wk
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
-1.86 vs -0.51 Sita + Met kg @ 26wk
NCT02284893 · Phase 3 · registry result, not featured evidence · background therapy
-1.91 vs -0.41 placebo kg @ 24wk
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
Fasting Plasma Glucose -1.62 vs -1.49 Glimepiride mmol/L @ 52wk10mg
absolute change · mmol/L
NCT02471404 · Phase 4 · registry result, not featured evidence
show 11 more results
-0.73 vs -1.29 Glimepiride mmol/L @ 52wk5 mg
NCT01006603 · Phase 4 · registry result, not featured evidence
-2.38 vs -1.62 Dapagliflozin mmol/L @ 26wk5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
-0.56 vs -0.34 placebo mmol/L @ 24wk*5 mg
NCT00757588 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -10.1 mg/dL as posted
-0.56 vs -1.62 Dapagliflozin mmol/L @ 26wk2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
-2.08 vs -1.49 Glimepiride mmol/L @ 52wk5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
-0.51 vs -0.29 placebo mmol/L @ 24wk*5 mg
NCT01619059 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -9.1 mg/dL as posted
-0.99 vs -1.01 Acarbose mmol/L @ 24wk
NCT02243176 · Phase 4 · registry result, not featured evidence
0.08 vs 0.19 placebo mmol/L @ 26wk
NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy
-1.77 vs -0.61 Sita + Met mmol/L @ 26wk*
NCT02284893 · Phase 3 · registry result, not featured evidence · background therapy · converted to mmol/L from -31.9 mg/dL as posted
-1.82 vs -0.29 placebo mmol/L @ 24wk*
NCT01646320 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -32.7 mg/dL as posted
-0.29 vs 0.15 placebo mmol/L @ 24wk
NCT01128153 · Phase 3 · registry result, not featured evidence
Time to Rescue Medication NA vs NA Glimepiride months @ 52wk10mg
time to event · months
NCT02471404 · Phase 4 · registry result, not featured evidence
show 2 more results
NA vs 21.3 Glimepiride months @ 156wkdapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
NA vs NA Glimepiride months @ 52wk5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
Rescue 18.6% (n=311) vs 21.4% (n=309) Glimepiride @ 52wk10mg
responder rate · % of participants
NCT02471404 · Phase 4 · registry result, not featured evidence
show 1 more result
8.3% (n=312) vs 21.4% (n=309) Glimepiride @ 52wk5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination

+ 49 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Prusogliptin's landscape · Saxagliptin's landscape